Amgen-backed Kernal Biologics pops off with $25M for mRNA platform

Kernal Biologics has bagged $25 million to advance its oncology messenger RNA (mRNA) tech, with backing from Big Pharma Amgen—and a former Bristol Myers Squibb leader joining the biotech’s exec team.